Precordial Pain
Precordial pain refers to discomfort or pain felt in the anterior chest wall, specifically in the region overlying the heart. While often a source of significant concern due to its potential association with serious cardiac conditions, precordial pain can arise from a wide range of causes, including musculoskeletal issues, gastrointestinal disorders, pulmonary problems, and psychological factors. Understanding its diverse origins is crucial for accurate diagnosis and effective management.
The biological basis of pain perception is complex, involving intricate neural pathways and neurochemical processes. Genetic factors are increasingly recognized as contributors to individual differences in pain sensitivity, perception, and susceptibility to various pain conditions. Research, including genome-wide association studies (GWAS), has identified numerous genetic associations with different types of pain. For example, studies have linked specific genetic variants to pain severity in dysmenorrhea, with an association near the nerve growth factor (NGF) locus[1], and to diabetic neuropathic pain, involving genes such asGFRA2 and regions on chromosomes 1p35.1 and 8p23.1 [2]. The genetic architecture of multisite chronic pain has also been explored[3], as have insights into the genetic underpinnings of back pain[4]and neuropathic pain following total joint replacement, highlighting a variant in the protein-kinase C gene[5]. Further research has investigated genetic influences on acute post-radiotherapy pain[6], chronic widespread pain[7], and acute post-surgical pain[8]. Additionally, the genetic polymorphism of pleiotrophin has been associated with pain experience[9]. These findings collectively demonstrate the significant role of inherited factors in shaping an individual’s experience of pain[10].
Clinically, evaluating precordial pain presents a diagnostic challenge due to its varied etiologies. Differentiating between life-threatening cardiac events, such as myocardial infarction, and less severe but often distressing non-cardiac causes is paramount. This differential diagnosis guides immediate medical interventions, further diagnostic testing, and long-term treatment strategies. The subjective nature of pain necessitates a comprehensive approach, combining patient history, physical examination, and diagnostic tools to accurately identify the underlying cause.
The social importance of precordial pain is substantial. It is a common reason for emergency department visits, placing a considerable burden on healthcare systems through extensive investigations and treatments. Beyond the immediate medical concern, precordial pain can significantly impact an individual’s quality of life, leading to limitations in daily activities, reduced work productivity, and substantial psychological distress, including anxiety and fear[11]. Public health initiatives often aim to raise awareness about chest pain symptoms to encourage timely medical evaluation, thereby improving outcomes for serious conditions and reducing the overall societal impact of pain.
Limitations
Section titled “Limitations”Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”Research into the genetic underpinnings of precordial pain faces several methodological and statistical challenges that influence the robustness and interpretability of findings. Many genetic association studies have been constrained by relatively small sample sizes, which can limit statistical power and increase the risk of false discoveries[8]. While larger meta-analyses, such as those combining discovery and replication sets, have achieved substantial sample sizes, the need for independent replications across diverse cohorts remains critical to confirm novel genetic associations and ensure their validity [4]. Furthermore, current genotyping platforms do not capture all known common genetic variations, representing only about two-thirds of the human genome, which may contribute to an underestimation of genetic effects and introduce potential biases in identifying true associations [8]. The estimation of genomic inflation in such studies also highlights the need for careful statistical control to avoid inflated effect sizes [4].
Phenotypic Heterogeneity and Generalizability
Section titled “Phenotypic Heterogeneity and Generalizability”Defining and measuring pain, including precordial pain, presents inherent challenges due to substantial interindividual variability in sensitivity and perception[12]. This phenotypic heterogeneity can complicate the identification of consistent genetic signals and their interpretation. Moreover, many genetic studies have been conducted predominantly within specific populations, such as European American cohorts, limiting the generalizability of findings to other ethnic groups [8]. Pain responses, including analgesic efficacy and genetic variations, are known to differ significantly across diverse ancestries, necessitating broader cross-population investigations to understand the full spectrum of genetic influences on precordial pain[8]. The complex interplay of precordial pain with psychiatric, personality, autoimmune, anthropometric, and circadian traits further underscores the difficulty in isolating specific genetic determinants and requires careful consideration in study design[12].
Unexplained Heritability and Mechanistic Gaps
Section titled “Unexplained Heritability and Mechanistic Gaps”Despite advancements in identifying genetic associations, a substantial portion of the heritability for pain traits, including those potentially related to precordial pain, remains unexplained by common genetic variants. For instance, SNP-based heritability estimates for back pain are observed to be around 6.9% on the observed scale, indicating that much of the genetic influence is yet to be fully elucidated[4]. Environmental factors and complex gene-environment interactions are recognized contributors to chronic pain, suggesting that purely genetic models may overlook critical modulatory elements[13]. Genetic association studies primarily identify statistical relationships, highlighting the ongoing need for extensive additional work to characterize the underlying biological mechanisms, especially when candidate genetic loci lack clear functional annotation [8]. This gap necessitates further research in both animal models and human studies to translate statistical associations into actionable biological insights and fully understand the etiology of precordial pain.
Variants
Section titled “Variants”Genetic variations play a crucial role in individual differences in pain perception and susceptibility to various pain conditions, including precordial pain. Understanding these variants and the genes they affect can shed light on the underlying biological mechanisms. The genes MNT, TAF4, MGAT5B, GCSAML, MIR4634 - LINC01951, and CNTN1, along with their associated single nucleotide polymorphisms (SNPs), contribute to diverse cellular processes that may influence the development or experience of chest pain.
The variant rs531961808 is associated with the MNT gene, which encodes a MAX network transcriptional repressor, playing a key role in regulating gene expression. MNT is involved in cell growth, differentiation, and apoptosis, processes that are fundamental to tissue health and stress responses. A variant like rs531961808 could subtly alter MNT’s regulatory function, potentially impacting pathways related to inflammation, cellular repair, or neurotransmission, all of which are relevant to pain perception. Similarly,rs530085784 is linked to TAF4, a component of the TFIID complex, which is essential for initiating gene transcription. Variations in TAF4 could broadly affect the efficiency of gene expression, thereby influencing a wide array of cellular functions, including those in cardiac or neuronal tissues that contribute to precordial pain. Research into chronic pain conditions has consistently identified a genetic component, highlighting the complex interplay of genetic factors in individual pain experiences or the integrity of cell membranes in the chest area, affecting pain perception. Genome-wide association studies (GWAS) have revealed multiple loci associated with various forms of chronic pain, suggesting a shared genetic landscape for different pain conditions. Dysmenorrheic pain, a form of visceral pain, is characterized by poor localization, referral to somatic structures, and strong autonomic and affective components, stemming from uterine prostaglandin production[1]. The clarity of these definitions is critical, as estimates for conditions like dysmenenorrhea are known to be affected by a lack of standardized diagnostic methodology [1]. Acute post-radiotherapy pain, for example, can be operationally defined by a specific pain score threshold to identify cases[6].
Key Variants
Section titled “Key Variants”Classification and Categorization of Pain Conditions
Section titled “Classification and Categorization of Pain Conditions”Pain conditions are categorized based on factors such as duration, location, and etiology. Categorical distinctions include acute versus chronic pain, with chronic back pain, for instance, being defined by a duration exceeding three months[4]. Pain can also be classified by anatomical site, with categories such as back pain, neck or shoulder pain, headache, abdominal pain, limb pain, and chest pain identified in survey instruments[2]. Specific pain subtypes like diabetic neuropathic pain or acute post-surgical pain are recognized based on their underlying causes or contexts[2]. Furthermore, pain can manifest as multisite chronic pain, indicating involvement across multiple body regions[3].
Measurement Approaches and Diagnostic Criteria for Pain
Section titled “Measurement Approaches and Diagnostic Criteria for Pain”The measurement of pain involves various approaches, including subjective severity scores and objective diagnostic criteria. For example, acute post-radiotherapy pain can be defined by a pain score threshold, with cases identified as those reporting a score of four or greater[6]. Research criteria often rely on detailed self-reported information about pain type and duration collected through structured questionnaires, enabling the differentiation of cases from controls[4]. These phenotypic measurements are crucial for genetic studies, allowing for the estimation of narrow-sense heritability, which quantifies the proportion of phenotypic variance attributable to additive genetic effects [2]. Pain problems can also be investigated in conjunction with other conditions, such as anxiety, highlighting the complex interplay of various health factors in pain experience[11].
Causes
Section titled “Causes”Precordial pain, like other forms of pain, arises from a complex interplay of genetic predispositions, environmental factors, and an individual’s overall health status. Research into the genetic architecture of various pain conditions, including chronic back pain, neuropathic pain, and multisite chronic pain, reveals common underlying mechanisms and risk factors that contribute to the experience and perception of pain.
Genetic Contributions to Pain Sensitivity and Perception
Section titled “Genetic Contributions to Pain Sensitivity and Perception”Genetic factors play a significant role in an individual’s susceptibility to and experience of pain. Genome-wide association studies (GWAS) have identified numerous genetic variants associated with different pain conditions, indicating a polygenic architecture where many genes contribute to overall risk. For instance, specific loci have been linked to pain severity in dysmenorrhea, such as an association at chromosome 1p13.2, near the nerve growth factor locus[1]. Similarly, genetic insights into back pain highlight a complex architecture involving multiple variants[4]. Neuropathic pain, a common and often debilitating form, has been associated with variants such as Chr8p21.3 (GFRA2) in diabetic neuropathic pain and a variant in the protein-kinase C gene after total joint replacement[2]. Sex-specific genetic influences have also been observed, with Chr1p35.1 (ZSCAN20-TLR12P) and Chr8p23.1 (HMGB1P46) showing associations with diabetic neuropathic pain[2]. The genetic architecture of multisite chronic pain also shows a significant genetic component, with pathway analyses identifying relevant biological processes[3]. These findings suggest that variations in genes involved in nerve function, inflammation, and pain signal processing can modulate an individual’s pain threshold and perception.
Interaction of Genetic Predisposition with Environmental Triggers
Section titled “Interaction of Genetic Predisposition with Environmental Triggers”The experience of pain is often a result of an intricate interaction between an individual’s genetic makeup and various environmental factors. While genetic variants may confer a predisposition, environmental triggers can determine the onset or severity of pain. For example, acute pain experienced post-surgery or post-radiotherapy in breast cancer patients has been shown to have a genetic component, indicating that an individual’s genetic profile can influence their response to external stressors or medical interventions[8]. Chronic pain, in particular, is understood to have both genetic and environmental risk components[13]. This interaction means that individuals with certain genetic vulnerabilities may be more likely to develop chronic or severe pain when exposed to specific environmental factors, such as injury, disease processes, or certain treatments. The joint investigation of adolescent anxiety and pain problems further illustrates this complex interplay, suggesting that genetic predispositions can interact with developmental and environmental contexts to manifest as co-occurring conditions[11].
Comorbidities and Other Modulating Factors
Section titled “Comorbidities and Other Modulating Factors”Beyond primary genetic and environmental influences, the presence of other health conditions and certain life circumstances can significantly contribute to the development and exacerbation of pain. Comorbidities are well-established risk factors for various pain types. For instance, diabetes is a known comorbidity that significantly increases the risk of neuropathic pain, with specific genetic associations identified for diabetic neuropathic pain[2]. Similarly, a strong link exists between anxiety and pain problems, where genetic investigations suggest shared underlying pathways contributing to both conditions[11]. Furthermore, medical treatments themselves can induce pain, as seen in acute post-radiotherapy pain in cancer patients or post-surgical pain, where an individual’s genetic background can modulate the pain response to these interventions[6]. The overall health status, presence of chronic diseases, and even the effects of certain medications can therefore act as important modulating factors in the manifestation and severity of pain.
Precordial pain, or chest pain, involves a complex interplay of biological processes spanning molecular, cellular, and systemic levels. The perception of pain is a subjective experience, but its origins are rooted in intricate physiological mechanisms that can be influenced by genetic predispositions, environmental factors, and various disease states. Understanding these biological foundations is crucial for comprehending the diverse manifestations and underlying causes of pain.
Neurobiological Basis of Pain Perception
Section titled “Neurobiological Basis of Pain Perception”Pain perception begins with nociception, the processing of noxious stimuli by the nervous system. This involves specialized sensory neurons that detect potentially damaging stimuli and transmit signals to the spinal cord and brain. The nervous system’s intricate network plays a critical role in both the initial detection and the subsequent sensitization that can lead to chronic pain states[3]. Such chronic pain phenotypes can involve structural and functional changes within the brain, affecting crucial processes like neurogenesis and synaptic plasticity[3].
At the tissue and organ level, the brain’s complex architecture, including areas involved in emotion, memory, and sensory processing, contributes to the overall pain experience. The integration of signals from peripheral nerves within the central nervous system determines the intensity and quality of perceived pain. This integration can be modulated by various factors, leading to heightened sensitivity or altered pain thresholds.
Molecular and Cellular Signaling Pathways
Section titled “Molecular and Cellular Signaling Pathways”The transmission and modulation of pain signals rely on a sophisticated network of molecular and cellular pathways. Key biomolecules, such as nerve growth factor (NGF), play a significant role in pain signaling and nerve function; genetic variants near the NGF locus have been associated with pain severity[1]. Cellular signaling cascades involving enzymes like protein-kinase C (PKC) are also implicated, with variants in the PKC gene highlighted in neuropathic pain symptoms[5]. Another critical receptor, GFR alpha 2 (GFRA2), has been linked to diabetic neuropathic pain, suggesting its involvement in cellular responses to nerve damage and subsequent pain transmission[2].
These biomolecules participate in signaling pathways that regulate neuronal excitability, neurotransmitter release, and the sensitization of pain pathways. For instance, NGF can promote the growth and survival of neurons and enhance their sensitivity to pain stimuli. The activation of specific receptors and downstream signaling molecules ultimately translates noxious stimuli into electrical signals, which are then relayed through the nervous system.
Genetic Architecture and Regulation of Pain
Section titled “Genetic Architecture and Regulation of Pain”Genetic mechanisms contribute significantly to an individual’s susceptibility to pain and their unique pain experience. Genome-wide association studies (GWAS) have identified numerous genetic variants associated with various pain conditions, including dysmenorrhea, back pain, neuropathic pain, and multisite chronic pain[1]. These studies indicate a complex genetic architecture underlying pain, where multiple genes and regulatory elements collectively influence pain sensitivity, perception, and the risk of developing chronic pain states[4]. The identified genetic loci can affect gene expression patterns, influencing the production or function of critical proteins, enzymes, and receptors involved in pain pathways.
Genetic predispositions can impact how an individual responds to noxious stimuli, processes pain signals, and even their susceptibility to conditions like chronic postoperative pain[14]. Furthermore, research suggests shared genetic influences between pain problems and other conditions, such as anxiety, highlighting the interconnectedness of biological systems[11]. This genetic landscape contributes to the heterogeneity observed in pain perception among individuals.
Systemic Interactions and Homeostatic Disruptions
Section titled “Systemic Interactions and Homeostatic Disruptions”Pain is not an isolated phenomenon but is deeply intertwined with systemic physiological processes and can result from or contribute to homeostatic disruptions. A significant cross-talk exists between the immune system and the nervous system in nociception and sensitization, particularly in the development of chronic pain[3]. Neuroinflammation, a process involving immune cells and inflammatory mediators in the nervous system, is implicated in neuropathic pain development[3].
Moreover, various comorbidities and systemic factors can influence pain. For example, obesity and chronic inflammation are often co-occurring conditions with chronic pain, where metabolically active adipose tissue can affect pain perception and inflammation[3]. Disruptions in homeostatic rhythms, such as sleep changes and loss of circadian rhythm, are common in individuals with chronic pain, and many chronic diseases, including pain conditions, exhibit diurnal patterns in symptom severity[3]. These systemic interactions underscore the holistic nature of pain and its profound impact on overall health and well-being.
Clinical Relevance
Section titled “Clinical Relevance”Precordial pain, like other forms of pain, carries significant clinical relevance across various domains, from understanding its underlying mechanisms to guiding personalized patient care. Research into the genetic architecture and clinical manifestations of diverse pain conditions provides valuable insights applicable to the comprehensive management of pain.
Genetic Insights and Risk Stratification
Section titled “Genetic Insights and Risk Stratification”Genome-wide association studies (GWAS) have profoundly advanced the understanding of the genetic architecture underlying various pain conditions, including back pain, dysmenorrhea, and neuropathic pain, by identifying specific genetic loci associated with pain severity and susceptibility[15]. This genetic understanding is crucial for risk stratification, as it allows for the identification of individuals with a higher predisposition to developing chronic or severe pain phenotypes, such as chronic postoperative pain or pain in cancer patients[14]. Such insights pave the way for personalized medicine approaches, where genetic profiles can inform early prevention strategies and tailored interventions before pain becomes debilitating.
The prognostic value of these genetic markers extends to predicting disease progression and long-term implications for patient well-being[14]. For instance, specific genetic variants can influence an individual’s pain sensitivity and their response to analgesic treatments, suggesting that genotype-guided therapy could optimize pain management[16]. Understanding these genetic underpinnings is essential for developing targeted pharmacogenomic strategies and improving outcomes for individuals experiencing diverse pain presentations.
Diagnostic Utility and Treatment Implications
Section titled “Diagnostic Utility and Treatment Implications”The identification of genetic predispositions to pain offers significant diagnostic utility, complementing traditional clinical assessments by providing objective markers for pain susceptibility and severity[15]. For example, specific genetic variants have been linked to the development of chronic postoperative pain or acute pain after radiotherapy, indicating their potential as biomarkers for early risk assessment in surgical and oncology settings[14]. This allows clinicians to proactively identify high-risk patients who may benefit from more intensive perioperative pain management or preventative strategies.
Genetic insights also profoundly influence treatment selection and monitoring strategies. Research highlights inter-individual variability in pain sensitivity and response to analgesics, including opioids, which can be influenced by genetic factors[16]. Studies on irritable bowel syndrome have explored the genotypes of pain and analgesia, demonstrating the potential for genetic profiling to guide the selection of effective pain relief medications[17]. This personalized approach to treatment selection, informed by genetic markers, can lead to improved efficacy, reduced adverse effects, and more effective long-term pain management and monitoring for various pain conditions.
Comorbidity and Overlapping Phenotypes
Section titled “Comorbidity and Overlapping Phenotypes”Pain often presents as part of complex clinical pictures, with significant associations and comorbidities that complicate diagnosis and management. Genetic studies reveal overlapping phenotypic architectures between different pain types, such as back pain and multisite chronic pain, suggesting common underlying biological pathways[15]. Furthermore, pain conditions frequently co-occur with psychological disorders; for instance, investigations into adolescent populations have identified joint genome-wide associations for anxiety and pain problems, highlighting a shared genetic vulnerability between these conditions[11]. This understanding of overlapping phenotypes is critical for a holistic patient assessment and for developing integrated treatment plans that address both the pain and its associated comorbidities.
The presence of comorbidities, such as anxiety or other chronic pain conditions, can significantly impact the progression and long-term implications of various pain presentations, influencing treatment response and overall quality of life[11]. Research into conditions like dysmenorrhea, for example, points to the broader syndromic presentations of pain, where localized discomfort may be part of a more systemic or genetically influenced pain sensitivity[1]. Recognizing these associations is vital for comprehensive care, enabling clinicians to anticipate complications, implement targeted prevention strategies, and tailor interventions to manage the complex interplay between pain and its related conditions.
Frequently Asked Questions About Precordial Pain
Section titled “Frequently Asked Questions About Precordial Pain”These questions address the most important and specific aspects of precordial pain based on current genetic research.
1. Why do I feel chest pain so intensely compared to others?
Section titled “1. Why do I feel chest pain so intensely compared to others?”Your genes play a significant role in how intensely you perceive pain. Research shows that inherited factors influence individual differences in pain sensitivity and perception. This means your unique genetic makeup can make you more or less sensitive to discomfort, including precordial pain, compared to someone else.
2. Does my family history mean my kids might have chest pain too?
Section titled “2. Does my family history mean my kids might have chest pain too?”While specific genes for precordial pain aren’t listed, pain sensitivity and susceptibility to various pain conditions are influenced by genetics. If pain conditions or high pain sensitivity run in your family, your children might inherit a predisposition to a similar pain experience. This doesn’t guarantee precordial pain, but their pain perception could be shaped by inherited factors.
3. Is my chronic chest pain “all in my head” because of anxiety?
Section titled “3. Is my chronic chest pain “all in my head” because of anxiety?”No, it’s not “all in your head,” but there’s a recognized connection between psychological factors like anxiety and pain experience. Studies have even explored the joint genetic underpinnings of anxiety and pain problems. Your genetic makeup can influence both your susceptibility to anxiety and how your body processes pain signals, making your pain experience very real.
4. Could a DNA test tell me why my chest hurts?
Section titled “4. Could a DNA test tell me why my chest hurts?”A DNA test could offer insights into your general pain sensitivity and how you perceive pain, as many genetic variants are linked to different types of pain. While specific genes for precordial pain aren’t yet clearly defined, it might show predispositions for higher pain perception or susceptibility to certain pain conditions. However, it wouldn’t diagnose the exact cause of your chest pain, which can have many origins.
5. Does my ethnic background change how I experience chest pain?
Section titled “5. Does my ethnic background change how I experience chest pain?”Yes, research indicates that pain responses and genetic variations can differ significantly across diverse ancestries. Many genetic studies have focused on specific populations, and findings aren’t always generalizable to others. Your ethnic background could influence your unique genetic profile, potentially affecting how you perceive and respond to pain, including precordial pain.
6. Why do some pain treatments work for others but not my chest pain?
Section titled “6. Why do some pain treatments work for others but not my chest pain?”Individual responses to pain treatments can be influenced by your genetic makeup. Just as genes affect pain perception, they can also impact how your body processes medications or responds to therapies. This genetic variability might explain why a treatment effective for someone else’s pain doesn’t work as well for your specific experience.
7. If I get chest pain often, am I genetically prone to chronic pain?
Section titled “7. If I get chest pain often, am I genetically prone to chronic pain?”Genetics do play a role in susceptibility to chronic pain conditions. Studies have identified genetic associations with chronic widespread pain and multisite chronic pain. While precordial pain has many causes, if it recurs frequently, your genetic predisposition could be a factor in your body’s tendency to develop or experience chronic pain.
8. My back hurts too; are my chest and back pains connected by genetics?
Section titled “8. My back hurts too; are my chest and back pains connected by genetics?”It’s possible. Genetic factors are linked to various pain conditions, including back pain and multisite chronic pain. While your chest pain might have a different immediate cause, your underlying genetic predisposition for general pain sensitivity could contribute to how you experience both types of discomfort.
9. Does my stress make my pain worse because of my genes?
Section titled “9. Does my stress make my pain worse because of my genes?”Your genes can influence how your body reacts to environmental factors like stress. Research highlights that anxiety and pain problems share genetic underpinnings. So, your genetic profile might make you more susceptible to experiencing increased pain, including precordial pain, during stressful periods.
10. Can I overcome my genetic predisposition for higher pain sensitivity?
Section titled “10. Can I overcome my genetic predisposition for higher pain sensitivity?”While your genes influence your baseline pain sensitivity, they don’t dictate your entire pain experience. Lifestyle factors, coping mechanisms, and medical treatments play a significant role in managing pain. Understanding your genetic predispositions can help tailor management strategies, allowing you to effectively mitigate the impact of your inherited pain sensitivity.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Jones, A. V. “Genome-wide association analysis of pain severity in dysmenorrhea identifies association at chromosome 1p13.2, near the nerve growth factor locus.”Pain, vol. 157, no. 11, 2016, pp. 2571-2581.
[2] Meng, W., et al. “A genome-wide association study finds genetic variants associated with neck or shoulder pain in UK Biobank.”Human Molecular Genetics, vol. 29, no. 11, 2020, pp. 1904-1913.
[3] Johnston, KJA et al. “Sex-stratified genome-wide association study of multisite chronic pain in UK Biobank.”PLoS Genet, 2021. PMID: 33830993.
[4] Freidin, M. B., et al. “Insight into the genetic architecture of back pain and its risk factors from a study of 509,000 individuals.”Pain, 2019.
[5] Warner, S. C., et al. “Genome-wide association scan of neuropathic pain symptoms post total joint replacement highlights a variant in the protein-kinase C gene.”European Journal of Human Genetics, 2017.
[6] Lee, E et al. “Genome-wide enriched pathway analysis of acute post-radiotherapy pain in breast cancer patients: a prospective cohort study.”Hum Genomics, vol. 13, no. 1, 2019, p. 28.
[7] Peters, MJ et al. “Genome-wide association study meta-analysis of chronic widespread pain: evidence for involvement of the 5p15.2 region.”Ann Rheum Dis, 2012. PMID: 22956598.
[8] Kim, H et al. “Genome-wide association study of acute post-surgical pain in humans.”Pharmacogenomics, 2009. PMID: 19207018.
[9] Saita, K et al. “Genetic polymorphism of pleiotrophin is associated with pain experience in Japanese adults: Case-control study.”Medicine (Baltimore), vol. 101, no. 37, 2022. PMID: 36123890.
[10] Sakaue, S et al. “A cross-population atlas of genetic associations for 220 human phenotypes.” Nat Genet, 2021. PMID: 34594039.
[11] Mascheretti, S et al. “Adolescent anxiety and pain problems: A joint, genome-wide investigation and pathway-based analysis.”PLoS One, 2023. PMID: 37146008.
[12] Fontanillas, P, et al. “Genome-wide association study of pain sensitivity assessed by questionnaire and the cold pressor test.”Pain, vol. 163, no. 9, Sept. 2022, pp. 1763–1776.
[13] McIntosh, A. M. et al. “Genetic and Environmental Risk for Chronic Pain and the Contribution of Risk Variants for Major Depressive Disorder: A Family-Based Mixed-Model Analysis.”PLoS Med, vol. 13, no. 8, 2016, p. e1002090, 27529168.
[14] van Reij, R. R. I., et al. “The association between genome-wide polymorphisms and chronic postoperative pain: a prospective observational study.”Anaesthesia, 2020.
[15] Freidin, M. B. et al. “Insight into the genetic architecture of back pain and its risk factors from a study of 509,000 individuals.”Pain, 30747904.
[16] Reyes-Gibby, C. C., et al. “Genome-wide association study suggests common variants within RP11-634B7.4 gene influencing severe pre-treatment pain in head and neck cancer patients.”Scientific Reports, 2016.
[17] Vollert, J., et al. “Genotypes of Pain and Analgesia in a Randomized Trial of Irritable Bowel Syndrome.”Frontiers in Psychiatry, 2022.